上海瀚辰星泰医药科技有限公司

Hanchen Xingtai is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH), as well as oncology and autoimmune diseases. Its lead candidate, HC-1102, is a potent GPR119 agonist currently in clinical development for the treatment of metabolic conditions. Hanchen Xingtai leverages its proprietary drug discovery platform to design highly selective molecules with optimized pharmacokinetic profiles. The company is backed by prominent venture capital firms such as Qiming Venture Partners and TF Capital.